Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 175-192 , June 2010

Fertility concerns and preservation in younger women with breast cancer

,Accepted 24 September 2009.

References 

  1. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;(1):105–109
  2. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229–239
  3. Putowski L, Kuczynski W. Strategies for fertility preservation after anti-cancer therapy. Ginekol Pol. 2003;74(8):638–645
  4. Tremellen K, Petrucco OM. Management of fertility issues in cancer survivors. Aust Fam Physician. 2003;32(1/2):15–18
  5. Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod Biomed Online. 2004;9(6):673–679
  6. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–95
  7. Oktay K. Fertility preservation: an emerging discipline in the care of young patients with cancer. Lancet Oncol. 2005;6(4):192–193
  8. Beerendonk CC, Braat DD. Present and future options for the preservation of fertility in female adolescents with cancer. Endocr Dev. 2005;8:166–175
  9. Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril. 2001;75(4):705–710
  10. Lowe MP, Bender D, Sood AK, Davis W, Syrop CH, Sorosky JI. Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril. 2002;77(1):188–189
  11. Plante M. Fertility preservation in the management of gynecologic cancers. Curr Opin Oncol. 2000;12(5):497–507
  12. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis. 2004;43(5):772–781
  13. Oktay K, Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod. 2004;19(3):477–480
  14. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–4353
  15. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med. 2005;353(1):64–73
  16. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–1729
  17. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466–472
  18. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990;1(3):183–188
  19. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001;(30):44–51
  20. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–4183
  21. Urbano MT, Tait DM. Can the irradiated uterus sustain a pregnancy? A literature review. Clin Oncol (R Coll Radiol). 2004;16(1):24–28
  22. Seymour JF. Ovarian tissue cryopreservation for cancer patients: who is appropriate?. Reprod Fertil Dev. 2001;13(1):81–89
  23. Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugieres L, Jouannet P. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod. 2002;17(6):1447–1452
  24. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol. 2005;23(16):3858–3859
  25. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405–1410
  26. Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN. Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod. 2005;20(12):3539–3546
  27. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma. 1999;33(1/2):65–76
  28. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod. 2004;19(6):1294–1299
  29. Stone ER, Slack RS, Novielli A, et al. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adriamycin and cytoxan followed by taxol (AC+T) in early stage breast cancer [abstract 224]. Breast Cancer Res Treat. 2000;64:61
  30. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045–1051
  31. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–2370
  32. Burstein HJ, Winer EP. Reproductive issues. In:  Harris JR editors. Diseases of the breast. Philadelphia, PA: Lippincott Williams & Wilkins; 2000;p. 1051–1059
  33. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol. 2002;21:141
  34. Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. J Clin Oncol. 2005;23(25):6002–6008
  35. Derman SG, Seifer DB. In vitro fertilization in the older patient. Curr Womens Health Rep. 2003;3(5):375–383
  36. Lobo RA. Menopause and aging. In:  Strauss JF,  Barbieri RL editor. Yen & Jaffe's reproductive endocrinology. Philadelphia, PA: Saunders, Elsevier Inc.; 2004;p. 421–452
  37. Bendsen E, Byskov AG, Andersen CY, Westergaard LG. Number of germ cells and somatic cells in human fetal ovaries during the first weeks after sex differentiation. Hum Reprod. 2006;21(1):30–35
  38. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342–1346
  39. Gosden R, Nagano M. Preservation of fertility in nature and ART. Reproduction. 2002;123(1):3–11
  40. Speroff L, Fritz MA. Menopause and the perimenopausal transition. Clinical gynecologic endocrinology and infertility. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;p. 621–88
  41. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428(6979):145–150
  42. Johnson J, Bagley J, Skaznik-Wikiel M, et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell. 2005;122(2):303–315
  43. Jarrell JF, Bodo L, YoungLai EV, Barr RD, O’Connell GJ. The short-term reproductive toxicity of cyclophosphamide in the female rat. Reprod Toxicol. 1991;5(6):481–485
  44. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50(7):1309–1314
  45. Fonseca R, Hartmann LC, Petersen IA, Donohue JH, Crotty TB, Gisvold JJ. Ductal carcinoma in situ of the breast. Ann Intern Med. 1997;127(11):1013–1022
  46. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355(9203):528–533
  47. AJCC . Breast. In:  Greene FL editors. AJCC cancer staging manual. New York, NY: Springer; 2002;p. 221–240
  48. Fisher B, Fisher ER, Redmond C, Brown A. Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res Treat. 1986;7(3):147–160
  49. Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968;168(3):337–356
  50. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90(18):1346–1360
  51. Liljegren G, Holmberg L, Bergh J, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17(8):2326–2333
  52. Clark RM, McCulloch PB, Levine MN, et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst. 1992;84(9):683–689
  53. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–970
  54. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–962
  55. Davis M. Ovarian reserve after chemotherapy. Endocr Abstr. 2005;9:49
  56. Weber B, Luporsi E. Ovarian toxicity of breast cancer chemotherapy. Eur J Cancer. 1998;34:42
  57. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod. 1993;8(12):2080–2087
  58. Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol. 1988;6(5):813–818
  59. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update. 2004;10(3):251–266
  60. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21(13):2600–2608
  61. Shamberger RC, Sherins RJ, Ziegler JL, Glatstein E, Rosenberg SA. Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. J Natl Cancer Inst. 1981;67(6):1213–1218
  62. Shamberger RC, Rosenberg SA, Seipp CA, Sherins RJ. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep. 1981;65(9/10):739–746
  63. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403–1409
  64. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Winer EP, Partridge AH. Chemotherapy-related amenorrhea in women with early breast cancer: the effect of paclitaxel or dose density. J Clin Oncol. 2006;24(18_suppl):10506;[meeting abstracts]
  65. Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Cancer Invest. 2008;26(5):491–498
  66. Fountzilas G, Dafni U, Gogas H, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008;19(5):853–860
  67. Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys. 2009;73(3):672–678
  68. Cobleigh MA, Bines J, Harris D. Amenorrhea following adjuvant chemotherapy for breast cancer (abstract). Proc Am Soc Clin Oncol. 1995;14:115
  69. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5(1):27–37
  70. Shenkenberg TD, Von Hoff DD. Possible mitoxantrone-induced amenorrhea. Cancer Treat Rep. 1986;70(5):659–661
  71. Reyno LM, Levine MN, Skingley P, Arnold A, Abu Zahra H. Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer. 1992;29A(1):21–23
  72. Plowchalk DR, Mattison DR. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol. 1991;107(3):472–481
  73. Rose DP, Davis TE. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980;40(11):4043–4047
  74. Mitwally MF, Casper RF. Aromatase inhibitors in ovulation induction. Semin Reprod Med. 2004;22(1):61–78
  75. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431–2442
  76. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 1990;61(6):861–865
  77. Padmanabhan N, Howell A, Rubens RD. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet. 1986;2(8504):411–414
  78. Padmanabhan N, Wang DY, Moore JW, Rubens RD. Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer Clin Oncol. 1987;23(6):745–748
  79. Tancini G, Bajetta E, Marchini S, Valagussa P, Bonadonna G. Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials. 1979;2(4):285–292
  80. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651–2658
  81. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol. 2005;23(22):5166–5170
  82. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990;65(4):847–850
  83. Bergh J, Jonsson PE, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001;40(2/3):253–281
  84. Paris F, Perez GI, Fuks Z, et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med. 2002;8(9):901–902
  85. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62(3):738–744
  86. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered?. Lancet Oncol. 2005;6(4):209–218
  87. Carter J, Auchincloss S, Sonoda Y, Krychman M. Cervical cancer: issues of sexuality and fertility. Oncology (Williston Park). 2003;17(9):1229–1234[discussion 1234–6, 1239, 1242]
  88. Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003;102(4):718–725
  89. Durrieu G, Rigal M, Bugat R, Lapeyre-Mestre M. Fertility and outcomes of pregnancy after chemotherapy in a sample of childbearing aged women. Fundam Clin Pharmacol. 2004;18(5):573–579
  90. Lavie O. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2004;103(5 Pt 1):997–998[author reply 998]
  91. Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Darai E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril. 2005;83(2):284–290[quiz 525–6]
  92. Duffy DA, Nulsen JC, Maier DB, Engmann L, Schmidt D, Benadiva CA. Obstetrical complications in gestational carrier pregnancies. Fertil Steril. 2005;83(3):749–754
  93. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997;43(2):183–190
  94. Lee D, Ouhibi N, Battaglia D. Cryopreservation of ovarian tissue: banking reproductive potential for the future. Curr Womens Health Rep. 2001;1(2):152–156
  95. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87(7):3045–3052
  96. Kenney LB, Laufer MR, Grant FD, Grier H, Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91(3):613–621
  97. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11(8):1620–1626
  98. Blumenfeld Z. Ovarian cryopreservation versus ovarian suppression by GnRH analogues: primum non nocere. Hum Reprod. 2004;19(8):1924–1925
  99. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981;1(8230):1132–1134
  100. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995;52(2):365–372
  101. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol. 1987;19(2):159–162
  102. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril. 2005;83(5):1333–1338
  103. Pereyra Pacheco B, Mendez Ribas JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol. 2001;81(3):391–397
  104. Trounson A, Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature. 1983;305(5936):707–709
  105. Fehilly CB, Cohen J, Simons RF, Fishel SB, Edwards RG. Cryopreservation of cleaving embryos and expanded blastocysts in the human: a comparative study. Fertil Steril. 1985;44(5):638–644
  106. Testart J, Lassalle B, Belaisch-Allart J, et al. High pregnancy rate after early human embryo freezing. Fertil Steril. 1986;46(2):268–272
  107. Testart J, Lassalle B, Belaisch-Allart J, et al. Human embryo viability related to freezing and thawing procedures. Am J Obstet Gynecol. 1987;157(1):168–171
  108. Cohen J, DeVane GW, Elsner CW, et al. Cryopreservation of zygotes and early cleaved human embryos. Fertil Steril. 1988;49(2):283–289
  109. Mandelbaum J, Belaisch-Allart J, Junca AM, et al. Cryopreservation in human assisted reproduction is now routine for embryos but remains a research procedure for oocytes. Hum Reprod. 1998;13(Suppl. 3):161–174[discussion 175–7]
  110. Azem F, Amit A, Merimsky O, Lessing JB. Successful transfer of frozen-thawed embryos obtained after subtotal colectomy for colorectal cancer and before fluorouracil-based chemotherapy. Gynecol Oncol. 2004;93(1):263–265
  111. Smith GD, Silva ESCA. Developmental consequences of cryopreservation of mammalian oocytes and embryos. Reprod Biomed Online. 2004;9(2):171–178
  112. Barbieri RL, Hornstein MD. Assisted reproduction. In:  Strauss JF,  Barbieri RL editor. Yen & Jaffe's reproductive endocrinology. Philadelphia, PA: Saunders, Elsevier Inc.; 2004;p. 839–873
  113. Stachecki JJ, Cohen J. An overview of oocyte cryopreservation. Reprod Biomed Online. 2004;9(2):152–163
  114. Atkinson HG, Apperley JF, Dawson K, Goldman JM, Winston RM. Successful pregnancy after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Lancet. 1994;344(8916):199
  115. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20(5):1213–1220
  116. Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20(10):2887–2892
  117. Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998;16(3):994–999
  118. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19(2):343–353
  119. Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol. 2005;20(6):343–360
  120. Kurbel S. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers. Med Hypotheses. 2005;64(6):1182–1187
  121. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab. 1997;82(7):2371–2374
  122. Leygue ER, Watson PH, Murphy LC. Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst. 1996;88(5):284–290
  123. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609–1618
  124. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001;61(13):5045–5050
  125. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002;16(6):592–594
  126. Rongieres-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod. 1999;14(3):683–688
  127. Ingerslev HJ, Hojgaard A, Hindkjaer J, Kesmodel U. A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate. Hum Reprod. 2001;16(4):696–702
  128. Omland AK, Abyholm T, Fedorcsak P, et al. Pregnancy outcome after IVF and ICSI in unexplained, endometriosis-associated and tubal factor infertility. Hum Reprod. 2005;20(3):722–727
  129. Poniatowski BC, Grimm P, Cohen G. Chemotherapy-induced menopause: a literature review. Cancer Invest. 2001;19(6):641–648
  130. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20(24):4621–4627
  131. Pritchard KI. Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?. J Clin Oncol. 2002;20(24):4611–4614
  132. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–2139
  133. Ravdin P. Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer. Lancet. 2002;359(9324):2126–2127
  134. Robertson A, Ginsburg E. Ovarian response and embryo yield after in vitro fertilization in patients undergoing embryo-banking prior to chemotherapy compared to the infertile population. Fertil Steril. 2005;84:S347–S348
  135. Fosas N, Marina F, Torres PJ, et al. The births of five Spanish babies from cryopreserved donated oocytes. Hum Reprod. 2003;18(7):1417–1421
  136. Tucker M, Morton P, Liebermann J. Human oocyte cryopreservation: a valid alternative to embryo cryopreservation?. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl. 1):S24–S27
  137. Miller KA, Elkind-Hirsch K, Levy B, Graubert MD, Ross SJ, Scott RT. Pregnancy after cryopreservation of donor oocytes and preimplantation genetic diagnosis of embryos in a patient with ovarian failure. Fertil Steril. 2004;82(1):211–214
  138. van Uem JF, Siebzehnrubl ER, Schuh B, Koch R, Trotnow S, Lang N. Birth after cryopreservation of unfertilized oocytes. Lancet. 1987;1(8535):752–753
  139. Chen C. Pregnancy after human oocyte cryopreservation. Lancet. 1986;1(8486):884–886
  140. Chen C. Pregnancies after human oocyte cryopreservation. Ann N Y Acad Sci. 1988;541:541–549
  141. Chen SU, Lien YR, Chen HF, Chang LJ, Tsai YY, Yang YS. Observational clinical follow-up of oocyte cryopreservation using a slow-freezing method with 1,2-propanediol plus sucrose followed by ICSI. Hum Reprod. 2005;20(7):1975–1980
  142. Toth TL, Lanzendorf SE, Sandow BA, et al. Cryopreservation of human prophase I oocytes collected from unstimulated follicles. Fertil Steril. 1994;61(6):1077–1082
  143. Gook DA, Edgar DH. Cryopreservation of the human female gamete: current and future issues. Hum Reprod. 1999;14(12):2938–2940
  144. Gook DA, Edgar DH, Stern C. Cryopreservation of human ovarian tissue. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl. 1):S41–S44
  145. Porcu E, Fabbri R, Seracchioli R, Ciotti PM, Magrini O, Flamigni C. Birth of a healthy female after intracytoplasmic sperm injection of cryopreserved human oocytes. Fertil Steril. 1997;68(4):724–726
  146. Porcu E. Oocyte freezing. Semin Reprod Med. 2001;19(3):221–230
  147. Posada MN, Kolp L, Garcia JE. Fertility options for female cancer patients: facts and fiction. Fertil Steril. 2001;75(4):647–653
  148. Boldt J, Cline D, McLaughlin D. Human oocyte cryopreservation as an adjunct to IVF-embryo transfer cycles. Hum Reprod. 2003;18(6):1250–1255
  149. Wang WH, Meng L, Hackett RJ, Odenbourg R, Keefe DL. Limited recovery of meiotic spindles in living human oocytes after cooling-rewarming observed using polarized light microscopy. Hum Reprod. 2001;16(11):2374–2378
  150. Jones A, Van Blerkom J, Davis P, Toledo AA. Cryopreservation of metaphase II human oocytes effects mitochondrial membrane potential: implications for developmental competence. Hum Reprod. 2004;19(8):1861–1866
  151. Hwu YM, Lee RKK, Su JT, Lin MW, Lin SPAT Fertilization and embryonic development of cryopreserved human immature oocytes collected at time of Caesarean section following intracytoplasmic injection. Fertil Steril. 1998;70:110–111
  152. Lee DM, Yeoman RR, Battaglia DE, et al. Live birth after ovarian tissue transplant. Nature. 2004;428(6979):137–138
  153. Newton H. The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Hum Reprod Update. 1998;4(3):237–247
  154. ASRM . Ovarian tissue and oocyte cryopreservation. Fertil Steril. 2008;90(5):S241–S246
  155. Almodin CG, Minguetti-Camara VC, Meister H, et al. Recovery of fertility after grafting of cryopreserved germinative tissue in female rabbits following radiotherapy. Hum Reprod. 2004;19(6):1287–1293
  156. Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA. 2001;286(12):1490–1493
  157. Oktay K, Aydin BA, Karlikaya G. A technique for laparoscopic transplantation of frozen-banked ovarian tissue. Fertil Steril. 2001;75(6):1212–1216
  158. Oktay K, Buyuk E, Rosenwaks Z, Rucinski J. A technique for transplantation of ovarian cortical strips to the forearm. Fertil Steril. 2003;80(1):193–198
  159. Schnorr J, Oehninger S, Toner J, et al. Functional studies of subcutaneous ovarian transplants in non-human primates: steroidogenesis, endometrial development, ovulation, menstrual patterns and gamete morphology. Hum Reprod. 2002;17(3):612–619
  160. Radford J. Autotransplantation of ovarian tissue and the risk of disease transmission. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl. 1):S48–S49
  161. Callejo J, Salvador C, Miralles A, Vilaseca S, Lailla JM, Balasch J. Long-term ovarian function evaluation after autografting by implantation with fresh and frozen-thawed human ovarian tissue. J Clin Endocrinol Metab. 2001;86(9):4489–4494
  162. Candy CJ, Wood MJ, Whittingham DG. Restoration of a normal reproductive lifespan after grafting of cryopreserved mouse ovaries. Hum Reprod. 2000;15(6):1300–1304
  163. Aubard Y, Piver P, Cogni Y, Fermeaux V, Poulin N, Driancourt MA. Orthotopic and heterotopic autografts of frozen-thawed ovarian cortex in sheep. Hum Reprod. 1999;14(8):2149–2154
  164. Baird DT, Webb R, Campbell BK, Harkness LM, Gosden RG. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at −196°C. Endocrinology. 1999;140(1):462–471
  165. Kim SS. Ovarian tissue banking for cancer patients. To do or not to do?. Hum Reprod. 2003;18(9):1759–1761
  166. Bedaiwy MA, Falcone T. Ovarian tissue banking for cancer patients: reduction of post-transplantation ischaemic injury: intact ovary freezing and transplantation. Hum Reprod. 2004;19(6):1242–1244
  167. Guinee VF, Olsson H, Moller T, et al. Effect of pregnancy on prognosis for young women with breast cancer. Lancet. 1994;343(8913):1587–1589
  168. Surbone A, Petrek JA. Childbearing issues in breast carcinoma survivors. Cancer. 1997;79(7):1271–1278
  169. Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer. 1999;85(11):2424–2432
  170. Steigrad S, Hacker NF, Kolb B. In vitro fertilization surrogate pregnancy in a patient who underwent radical hysterectomy followed by ovarian transposition, lower abdominal wall radiotherapy, and chemotherapy. Fertil Steril. 2005;83(5):1547–1549
  171. Zhang J, Grifo JA, Del Priore G. Gestational carrier pregnancy with oocytes obtained during surgery for stage IIIc ovarian cancer after controlled ovarian stimulation. Fertil Steril. 2005;83(5):1547–1549
  172. Galbraith M, McLachlan HV, Swales JK. Commercial agencies and surrogate motherhood: a transaction cost approach. Health Care Anal. 2005;13(1):11–31
  173. Fett JD. Peripartum cardiomyopathy (PPCM) in both surrogate and biological mother. Hum Reprod. 2005;20(9):2666–2668
  174. Landon MB, Catalano PM, Gabbe SG. Diabetes mellitus. In:  Gabbe SG,  Niebyl JR,  Simpson JL editor. Obstetrics: normal and problem pregnancies. Philadelphia, PA: Hartcourt Health Sciences Company; 2002;p. 1081–1116
  175. Sibai BM. Hypertension. In:  Gabbe SG,  Niebyl JR,  Simpson JL editor. Obstetrics: normal and problem pregnancies. Philadelphia, PA: Hartcourt Health Sciences Company; 2002;p. 945–1004
  176. Rideout WM, Eggan K, Jaenisch R. Nuclear cloning and epigenetic reprogramming of the genome. Science. 2001;293(5532):1093–1098
  177. Hubner K, Fuhrmann G, Christenson LK, et al. Derivation of oocytes from mouse embryonic stem cells. Science. 2003;300(5623):1251–1256
  178. Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ. Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature. 2004;427(6970):148–154
  179. Friedrich MJ. George Daley, MD., PhD, talks about the clinical promise of stem cell research. JAMA. 2005;293(7):787–789
  180. Rideout WM, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002;109(1):17–27

PII: S1040-8428(09)00196-6

doi: 10.1016/j.critrevonc.2009.09.006

Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 175-192 , June 2010

Article Tools